Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma or grade III malignant glioma
NCT02026271Phase 1Completed
- Sponsor
- Alaunos Therapeutics
- Start
- Jun 2015
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ad-rts-hil-12 in glioblastoma (GBM) and malignant glioma (2 arms), sponsored by Alaunos Therapeutics. Primary endpoint: Safety and Tolerability of Varying Doses of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex at 3 years. Started Jun 2015; status: completed.
02
Drugs
ad-rts-hil-12
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT02026271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026271.